Trial Profile
Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2016
Price :
$35
*
At a glance
- Drugs ACH 24 (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Ache Laboratories
- 15 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
- 18 Apr 2014 New trial record